{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:59:15Z","timestamp":1761663555679},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.jhep.2016.12.002","type":"journal-article","created":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T18:30:43Z","timestamp":1481394643000},"page":"711-717","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience"],"prefix":"10.1016","volume":"66","author":[{"given":"Alessandra","family":"Mangia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Susser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Piazzolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Agostinacchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Spinzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Immacolata","family":"Carraturo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Potenza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruggero","family":"Losappio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Arleo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Miscio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Sarrazin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Copetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.12.002_b0005","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL Recommendations on treatment of hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.12.002_b0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL Recommendations on treatment of hepatitis C 2016","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.12.002_b0015","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 Infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.12.002_b0020","unstructured":"SASL www.hepatitis-schweiz.ch Treatment of chronic Hepatitis C September 2016 update SASL-SSI expert opinion Statement."},{"key":"10.1016\/j.jhep.2016.12.002_b0025","unstructured":"Aghemo A, Bruno R, Ciancio A, Coco B, Petta S, Toniutto P, et al. Documento di indirizzo dell\u2019Associazione Italiana per lo Studio del Fegato per l\u2019uso razionale di antivirali diretti di seconda generazione nelle categorie di pazienti affetti da epatite C cronica ammesse alla rimborsabilit\u00e0 in Italia; (2014, reviewed in September 2015th). Retrieved from: http:\/\/www.webaisf.org\/media\/33882\/documento_hcv_22set.2015.pdf."},{"key":"10.1016\/j.jhep.2016.12.002_b0030","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.12.002_b0035","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.12.002_b0040","article-title":"Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower SVR rates in real life than expected from clinical trials","author":"Tacke","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.12.002_b0045","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2016-311609","article-title":"Effectiveness and safety of Sofosbuvir and Ribavirin for the Treatment of HCV Genotype 2 infection: results of the real-world, clinical practice HCV-TARGET Study","author":"Welzel","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.12.002_b0050","unstructured":"American Association for the Study of Liver Diseases, Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Retrieved from: http:\/\/www.hcvguidelines.org\/."},{"key":"10.1016\/j.jhep.2016.12.002_b0055","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/hepr.12505","article-title":"High incidence of the hepatitis C virus recombinant 2k\/1b in Georgia: Recommendations for testing and treatment","volume":"45","author":"Karchava","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2016.12.002_b0060","doi-asserted-by":"crossref","unstructured":"Susser S, Dietz J, Barak M, Schlevogt B, Daniel R, Piazzolla V et al. Prevalence and clinical importance of hepatitis C virus genotype 2K\/1B chimeras. Abstract presented at the International Liver Congress EASL - European Association for the Study of the Liver Barcelona, Spain 13\u201317 April 2016.","DOI":"10.1016\/S0168-8278(16)01638-X"},{"key":"10.1016\/j.jhep.2016.12.002_b0065","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.gastro.2010.05.079","article-title":"An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a radid virologic response","volume":"139","author":"Mangia","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.12.002_b0070","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.12.002_b0075","doi-asserted-by":"crossref","first-page":"W5","DOI":"10.1093\/nar\/gkn201","article-title":"NCBI BLAST: a better web interface","volume":"36","author":"Johnson","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jhep.2016.12.002_b0080","unstructured":"World Health Organization. Hepatitis C virus. World Health organization (WHO). Retrieved from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/."},{"key":"10.1016\/j.jhep.2016.12.002_b0085","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1478-3231.2011.02539.x","article-title":"A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel","volume":"31","author":"Cornberg","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.12.002_b0090","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/23744235.2015.1113438","article-title":"Treatment of hepatitis C virus infection for adult and children: Updated Swedish consensus recommendations","volume":"48","author":"Lagging","year":"2016","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.jhep.2016.12.002_b0095","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/jvh.12312","article-title":"Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection, an open-label phase 3 trial","author":"Omata","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2016.12.002_b0100","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir in Genotypes 2 or 3 VALENCE Trial","volume":"22","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.12.002_b0105","doi-asserted-by":"crossref","first-page":"S621","DOI":"10.1016\/S0168-8278(15)30978-8","volume":"62","author":"Dieterich","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.12.002_b0110","article-title":"Efficacy of sofosbuvir plus ribavirin in Veterans with hepatitis C viruss genotype 2 infection compensated cirrhosis and multiple comorbidities","author":"Ho","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.12.002_b0115","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.gastro.2016.05.049","article-title":"Effectiveness of Sofosbuvir, Ledipasvir\/Sofosbuvir, or Paritaprevir\/Ritonavir\/Ombitasvir and Dasabuvir regimens for treatment of patients with hepatitis C inn the Veterans Affairs National Health Care System","volume":"151","author":"Ioannou","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.12.002_b0120","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with HCV cirrhosis in a multicenter cohort of the Freanch early access programme (ANRS CUPIC)","author":"Hezode","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.12.002_b0125","doi-asserted-by":"crossref","first-page":"PS021","DOI":"10.1016\/S0168-8278(16)00034-9","article-title":"High efficacy of sofosbuvir\/velpatasvir\/GS9857 with or without RBV for 12 weeks in direct acting antiviral experienced patients with genotype 1 HCV infection","volume":"64","author":"Lawitz","year":"2016","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816307073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816307073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T11:53:30Z","timestamp":1568634810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816307073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0168827816307073"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.12.002","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}